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AbstrACt
Objective Patients with multiple chronic health conditions 
are often managed in a disjointed fashion in primary care, 
with annual review clinic appointments offered separately 
for each condition. This study aimed to determine the cost- 
effectiveness of the 3D intervention, which was developed 
to improve the system of care.
Design Economic evaluation conducted alongside a 
pragmatic cluster- randomised trial.
setting General practices in three centres in England and 
Scotland.
Participants 797 adults with three or more chronic 
conditions were randomised to the 3D intervention, while 
749 participants were randomised to receive usual care.
Intervention The 3D approach: comprehensive 
6- monthly general practitioner consultations, supported by 
medication reviews and nurse appointments.
Primary and secondary outcome measures The 
primary economic evaluation assessed the cost per 
quality- adjusted life year (QALY) gained from the 
perspective of the National Health Service (NHS) and 
personal social services (PSS). Costs were related to 
changes in a range of secondary outcomes (QALYs 
accrued by both participants and carers, and deaths) in a 
cost–consequences analysis from the perspectives of the 
NHS/PSS, patients/carers and productivity losses.
results Very small increases were found in both QALYs 
(adjusted mean difference 0.007 (−0.009 to 0.023)) and 
costs (adjusted mean difference £126 (£−739 to £991)) 
in the intervention arm compared with usual care after 
15 months. The incremental cost- effectiveness ratio was 
£18 499, with a 50.8% chance of being cost- effective at a 
willingness- to- pay threshold of £20 000 per QALY (55.8% 
at £30 000 per QALY).
Conclusions The small differences in costs and outcomes 
were consistent with chance, and the uncertainty 
was substantial; therefore, the evidence for the cost- 
effectiveness of the 3D approach from the NHS/PSS 
perspective should be considered equivocal.
trial registration number ISCRTN06180958
IntrODuCtIOn
The number of patients living with multiple 
chronic health conditions (multimorbidity) 
is increasing in developed countries as the 
population ages.1 Multimorbidity is asso-
ciated with poor health- related quality of 
life,2 3 higher use of health services and higher 
costs.4 5 Multimorbidity is common for older 
adults (with a prevalence of up to 98%),4 
leading to a substantial economic burden.6
Care pathways for patients with multi-
morbidity are often poorly coordinated and 
burdensome for patients. Each condition 
may be treated separately, which fails to take 
account of interactions between diseases.1 
There have been relatively few randomised 
controlled trials (RCTs) of interventions 
designed to address issues affecting multi-
morbid patients, with mixed findings leading 
to substantial uncertainty about the effective-
ness of such interventions.7 Evidence on the 
cost- effectiveness of interventions remains 
even more limited and the evidence that is 
available is inconsistent.7–9 A recent review of 
comprehensive care programmes for multi-
morbidity found no evidence that such inter-
ventions reduce healthcare costs or primary 
care visits.10 Several reviews have highlighted 
the need for research on new interventions, 
strengths and limitations of this study
 ► This economic evaluation was conducted alongside 
the largest randomised controlled trial of an inter-
vention for managing multimorbid patients in prima-
ry care.
 ► Data collection was meticulous and high question-
naire return rates were achieved.
 ► Data on the use of care homes, which may contrib-
ute significantly to social care costs, were not avail-
able to include in the economic evaluation.
 ► Estimates of healthcare costs for this type of inter-
vention have wide CIs, even with a substantial sam-
ple size.
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box 1 the 3D model and usual care in the uK
the 3D model
3D is a name used to allude to the concept of wholeness, while also 
acting as a mnemonic for ‘dimensions of health, depression and drugs’.
 ► Based on a patient- centred care model.
 ► Practice level changes to improve continuity of care and to re-
place disease- focused reviews of each health condition with one 6 
monthly comprehensive 3D review with a named GP.
 ► Each 3D review consisted of three elements;
1. Nurse consultation to identify health problems most important to 
the patient, issues with quality of life, screening for depression, 
collecting health data, for example, blood pressure and informa-
tion relevant to the patient’s specific conditions.
2. Pharmacist review of medication from medical records, aiming to 
simplify and optimise drug treatment. Pharmacists were asked to 
identify non- essential drugs that could be stopped and essential 
drugs that should be started, and to seek ways to simplify drug 
treatment regimes, for example, by making all doses once daily.
3. GP reviewed data from nurse and pharmacist, and agreed a 
health plan with the patient, which was given to them as a print-
ed copy.
 ► An interactive computerised template enabled sharing of data 
between the clinicians, tailored the review to the patient’s specif-
ic conditions, contained automated checks and generated printed 
summaries to enable sharing of information and plans with the 
patient.
 ► Strategies to encourage implementation were used, including train-
ing, monthly feedback about implementation and financial incen-
tives for completed reviews.
usual care in the uK
 ► Review of chronic conditions is mainly carried out by nurses in pri-
mary care using disease- specific data- entry screens or templates.
 ► Nurses commonly specialise in particular conditions and review 
each disease separately.
 ► Chronic disease reviews mainly focus on meeting the requirements 
of the Quality and Outcomes Framework (QOF) pay- for- performance 
scheme.
including assessment of cost- effectiveness.1 7 11 The incon-
sistency in the evidence for cost- effectiveness provided a 
clear indication that a large, well- conducted trial with an 
integral economic evaluation needed to be carried out.
The ‘3D’ intervention was developed to address the 
issues associated with managing patients with multimor-
bidity in primary care in the UK. The intervention was 
based on a patient- centred care model and aimed to 
improve continuity of care with caregivers in general 
practitioner (GP) surgeries, reduce patient burden in 
accessing healthcare and increase patient involvement 
in decision- making about their care (see box 1). Based 
on the seminal work of Stewart,12 the concept of patient- 
centred care includes a focus on the patient’s individual 
illness experience, an integrated biopsychosocial perspec-
tive, seeking to find common ground with the patient and 
agreeing management plans and enhancing a continuing 
relationship between the patient and doctor. We sought 
to apply these principles within the 3D intervention. The 
3D randomised trial assessed the effectiveness of the 3D 
approach compared with usual care, and incorporated 
an embedded process evaluation. The trial did not find 
any differences in health- related quality of life over 15 
months of follow- up, but the intervention did lead to 
improved patient- centred care.13 14 Here, we report the 
results of the economic evaluation conducted alongside 
the 3D trial.
MethODs
Design: the 3D trial
Full details of the study design, eligibility criteria, recruit-
ment process and clinical effectiveness results are given 
elsewhere.14 15 All patients and practices gave written 
informed consent to participate in the study. In brief, the 
pragmatical 3D cluster randomised trial compared the 
effectiveness and cost- effectiveness of a complex inter-
vention for multimorbidity with usual care delivered 
in 33 general practices in Scotland and England. The 
target patients were adults with multimorbidity, defined 
as having three or more chronic conditions from those 
included in the National Health Service (NHS) Quality 
and Outcomes Framework.16 Clinical staff in interven-
tion practices attended two half- day 3D training sessions. 
Participants in the intervention arm were offered 
6- monthly holistic reviews of their health problems. 
Each review consisted of a nurse review appointment to 
collect relevant clinical information, a medication review 
conducted by a pharmacist and an extended appoint-
ment for the patient to discuss their conditions with a 
named GP. An individual health plan was negotiated with 
patients, detailing their own priorities for managing their 
conditions. The primary outcome measure for effective-
ness was health- related quality of life at 15 months after 
randomisation, measured using the EQ- 5D- 5L.17
The primary economic cost–utility analysis was 
conducted from the NHS and personal social services 
(PSS) perspective over 15 months of follow- up. A 
secondary analysis was conducted from the perspective of 
patients and carers.
Patient and public involvement
An active group of up to 14 patients and carers provided 
a service user perspective, contributing to refinement 
of the research questions, design of the intervention, 
design of outcome measures, analysis of qualitative data, 
patient newsletters, the study website and interpretation 
of findings. All participants were given a summary of the 
findings and a link to the published paper describing the 
main results. One of the outcome measures in the study 
was treatment burden and this was compared between 
trial arms.
Measures
Outcome measurement
The primary economic outcome measure was quality- 
adjusted life years (QALYs). EQ- 5D- 5L measurements 
were collected by postal questionnaires at baseline, 9 
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months and 15 months post- recruitment, supplemented 
by telephone collection for non- responders. Utility scores 
based on a UK population were derived from responses 
to the EQ- 5D- 5L cross- mapped to valuations obtained for 
the EQ- 5D- 3L instrument.18 This was a change (approved 
by the Independent Data Monitoring Committee) to the 
analysis originally planned, as the National Institute for 
Health and Care Excellence (NICE) issued a position 
statement recommending this approach19 subsequent to 
the design of the study but prior to analysis. QALYs over 
the 15- month period were formed from these valuations 
by means of linear interpolation and an area under the 
curve calculation. Patients who died during follow- up 
were treated as if their most recent utility score was rele-
vant until death, and set to zero immediately at death. 
Carers also completed the EQ- 5D- 5L instrument at the 
same timepoints as patients.
Resource-use measurement
As the trial population had multimorbidity, resource use 
related to any health condition experienced by the partic-
ipant was considered relevant.
Staff training attendance records were kept to track 
resources used to deliver the training programmes for 
GPs, nurses and receptionists, including trainee and 
trainer delivery time (and preparation time), travel 
costs and course materials. 3D GP appointments, nurse 
appointments and pharmacist reviews were captured 
by downloading routine GP records, supplemented by 
manual data capture by researchers reviewing partici-
pants’ medical records at the end of the trial.
Data on medications prescribed and tests/investiga-
tions in primary care were extracted from downloads of 
routine GP records. Details of the number and duration 
of primary care consultations (other than 3D reviews) 
were similarly extracted. These included face- to- face, 
telephone and home consultations with doctors, nurses 
or healthcare assistants based in general practice. Dura-
tion details were not available for practices in Scot-
land. Therefore, an average duration for each type of 
consultation by each staff type in each arm was derived 
using available data (practices in England only) and 
applied to all relevant consultations. The research team 
collected NHS secondary care data from participants’ 
GP records.
To assess travel costs, the patient’s normal transport 
method for GP appointments and the cost (for public 
transport) or mileage (for private transport) were 
collected in the patient- reported questionnaire at base-
line, along with usual practice with regards to time off 
work, and details of whether the participant paid prescrip-
tion charges or not. NHS community care, care from 
social services, time off work for patients and carers to 
attend hospital appointments and over- the- counter medi-
cation expenditure were captured in the patient- reported 
questionnaires at 9 and 15 months, as were private use of 
treatments and therapies.
Valuation of resource use
Unit costs for NHS staff time for training and delivery of 
the intervention were based on the most recently available 
national estimates.20 Actual expenses relating to training 
materials, refreshments and staff travel were recorded. 
Because only some GPs and a small proportion of patients 
in each practice participated in the trial, costs were adjusted 
to estimate the cost of training a full practice, divided by 
the number of eligible patients in the practice and annual-
ised over an estimated 5- year period of relevance. Medica-
tion costs were downloaded directly as part of the routine 
GP records, supplemented by estimates from the British 
National Formulary where necessary.21 Patient prescription 
charges were subtracted from the NHS perspective medica-
tion costs. Community and primary care costs were based 
on recent national estimates.20
Secondary care contacts were assigned to a healthcare 
resource group (groups of events that have been judged 
to consume similar levels of resources) and costed based 
on national reference costs.22 Productivity costs for both 
patients and carers were estimated based on average 
weekly earnings stratified by age group.23 Mileage costs 
were estimated using UK government allowances.24 Costs 
for over- the- counter medication and private therapies 
and treatments were all reported directly by patients. 
Unit costs used in the analyses are detailed in online 
supplementary appendix 1.14
All costs were reported in 2015/2016 pounds ster-
ling, adjusted for inflation where necessary.25 Costs 
and outcomes occurring during the final 3 months of 
follow- up were discounted in line with NICE guidance 
(currently 3.5%).26 Dates were not available for all types 
of resource use measured in the trial; in these cases, 50% 
of the costs incurred in the final 6 months of follow- up 
were subjected to discounting.
Data cleaning and missing costs and outcomes
Data cleaning was undertaken prior to unblinding. Ques-
tionnaires were not classed as 'missing data' for the cost 
analysis unless the questionnaire was not returned or the 
majority of responses were uninterpretable. Medication 
costs downloaded from practices were manually amended 
where they were clearly wrong on visual inspection (eg, 
a prescription for a salbutamol inhaler with a recorded 
cost of over £1000). The primary analysis included all 
participants using imputation to predict missing costs 
and outcomes.27 Data imputed (using chained equation 
multiple imputation methods) for the main statistical 
analysis were used for the economic evaluation.13 14 28 29 
To facilitate convergence of the imputation model, costs 
were imputed using aggregated cost categories (medica-
tions, pharmacy reviews, secondary care, primary care, 
social care and other types of care) rather than at the 
level of individual resource- use items.
economic analyses
Statistical analyses were conducted using Stata 14.2.30 All 
analyses were by ’intention to treat’ (comparing the two 
copyright.
 o
n
 January 27, 2020 at University of East Anglia. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030110 on 19 January 2020. Downloaded from 
4 Thorn J, et al. BMJ Open 2020;10:e030110. doi:10.1136/bmjopen-2019-030110
Open access 
Table 1 Baseline characteristics of practices and patients
Usual care
(n=17 practices, 749 patients)
Intervention
(n=16 practices, 797 patients)
Patients
Age: mean (SD) 70.7 (11.4) 71.0 (11.6)
Female: no. (%) 377 (50%) 406 (51%)
White ethnicity: no./total no. (%) 729/739 (99%) 775/780 (99%)
Fully retired from work: no./total no. (%) 512/721 (71%) 525/759 (69%)
No. of long- term conditions from QOF: median (IQR) 3.0 (3.0 to 3.0) 3.0 (3.0 to 3.0)
No. of self- reported conditions: median (IQR), n 7.0 (5.0 to 10.0), 748 7.0 (5.0 to 9.0), 795
Long- term conditions* no. (%) with:
  Cardiovascular disease or chronic kidney disease† 698 (93%) 747 (94%)
  Stroke or transient ischaemic attack 241 (32%) 286 (36%)
  Diabetes 401 (54%) 411 (52%)
  Chronic obstructive pulmonary disease or asthma 382 (51%) 388 (49%)
  Epilepsy 35 (5%) 41 (5%)
  Atrial fibrillation 249 (33%) 281 (35%)
  Serious mental illness‡ 37 (5%) 29 (4%)
  Depression 283 (38%) 276 (35%)
  Dementia 27 (4%) 33 (4%)
  Learning disability 7 (1%) 7 (1%)
  Rheumatoid arthritis 55 (7%) 48 (6%)
EQ- 5D- 5L score: mean (SD), n 0.542 (0.292), 747 0.574 (0.282), 795
*Conditions with similar clinical management were grouped and counted once only.
†Including coronary heart disease, hypertension, heart failure, peripheral arterial disease, chronic kidney disease stages 3 to 5.
‡Including schizophrenia, psychosis, bipolar disease.
QOF, Quality and Outcomes Framework.
groups as randomised and including all patients in the 
primary analysis). A glossary of economic terms is given in 
online supplementary appendix 2, and more details may 
be found in Morris et al.31
A cost–utility analysis was conducted from the NHS/PSS 
perspective corresponding to the NICE reference case.26 
The incremental mean difference in QALYs between the 
two arms of the trial and 95% CIs were derived. Overall 
mean NHS/PSS costs, and SEs for both arms of the trial 
were calculated. The incremental mean difference in 
total costs between the two arms of the trial and 95% CIs 
were estimated.
Cost and QALY data were combined to calculate an 
incremental cost- effectiveness ratio (ICER) and net 
monetary benefit (NMB) statistic32 from the NHS/PSS 
perspective. In the primary analysis we estimated whether 
the 3D approach was cost- effective at the established NICE 
thresholds of £20 000 and £30 000 per QALY gained. The 
probability that the 3D approach was cost- effective at 
various societal 'willingness to pay for a QALY' thresholds 
was depicted using a cost- effectiveness acceptability curve 
(CEAC). All measures of cost- effectiveness (ICER, CEAC 
and NMB) and CIs were derived parametrically using 
the output of seemingly- unrelated regression analysis to 
account for the correlation between costs and outcomes, 
and controlling for baseline imbalance in utility for the 
QALY equation33. Clustering within GP practices was 
accounted for by including the randomisation variables 
in the regression.
As the broader societal perspective also has relevance, 
the costs of each component of the intervention were 
estimated separately from the NHS/PSS perspective 
(ie, including all resources supplied by the healthcare 
provider), the patient/carer perspective (ie, including 
all costs borne by the participants themselves) and the 
productivity perspective (ie, taking into account time off 
work) and related to changes in a range of secondary 
outcomes in a cost–consequences analysis.34 Conse-
quences included QALYs accrued by both participants 
and carers, and deaths. The cost–consequences analysis 
was based on available cases, which differed in number 
for each type of healthcare resource or outcome; an avail-
able case was defined as an individual having complete 
data for each relevant timepoint. Linear regression 
output was used to derive CIs parametrically, accounting 
for clustering within practices.
Sensitivity analyses
One- way sensitivity analyses were used to judge the poten-
tial impact of sources of uncertainty. This included an 
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Figure 1 Trial profile † † Salisbury C, man M- S, Bower P, et al. Management of multimorbidity using a patient- centred care 
model: A pragmatic cluster- randomised trial of the 3D approach. The Lancet 2018;392(10141):41–50. *categorised according to 
exclusion criteria.
analysis excluding participants who died to assess the 
impact of the imbalance in deaths between arms, and an 
analysis without discounting either costs or outcomes (ie, 
a discount rate of zero) to assess the impact of the discount 
rate. A complete- case analysis was also conducted to assess 
the impact of the imputation process; a complete case was 
defined as a participant for whom full resource- use data 
and full outcome data were available.
results
The results are reported according to the specifications of 
the Consolidated Health Economic Evaluation Reporting 
Standards statement.35 Baseline characteristics of the 
practices and patients are given in table 1,13 and the flow 
of patients through the study is illustrated in figure 1.13
Missing data
Sixteen practices (797 participants) were randomised 
to be offered the 3D approach, while 17 practices (749 
participants) were randomised to receive usual care. 
Missing data occurred for a number of reasons, including 
withdrawal from the trial, or leaving the practice. Twelve 
participants (1.5%) in the 3D arm and six (0.8%) in the 
control arm had no information on secondary care use 
because it was not possible to locate their medical records 
(p=0.2). Practice downloads of medication and investiga-
tion data failed for 18 participants (2.3%) in the interven-
tion arm and eight (1.1%) in the usual care arm (p=0.07), 
while 19 (2.4%) and 10 (1.3%) 3D and usual care partic-
ipants, respectively, were missing consultation data 
from practice downloads (p=0.13). Not all participants 
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Table 2 Cost- effectiveness of the 3D approach from an NHS and personal social services perspective
Usual care
mean (SE)
n=749
Intervention
mean (SE)
n=797
Incremental difference 
(95% CI)
Costs (£)
  Unadjusted costs from the NHS/PSS 
perspective
6032 (362) 6124 (317)
  Adjusted costs from the NHS/PSS perspective 6014 (343) 6140 (333) 126 (−739 to 991)
Outcomes
  Unadjusted QALYs over 15 months of follow- 
up
0.651 (0.013) 0.691 (0.012)
  Adjusted QALYs over 15 months of follow- up 0.668 (0.006) 0.675 (0.006) 0.007 (−0.009 to 0.023)
Cost- effectiveness statistics
  ICER: £18 499
  Net monetary benefit at £20 000 (95%CI): £10 (−956 to 977)
Net monetary benefit at £30 000 (95%CI): £78 (−974 to 1130).
Cost estimates were adjusted for randomisation variables; QALY estimates were adjusted for randomisation variables and baseline utility.
CI, confidence interval; ICER, incremental cost- effectiveness ratio; NHS, National Health Service; PSS, personal social services; QALY, 
quality- adjusted life year; SE, standard error.
Figure 2 Cost- effectiveness acceptability curve from the 
NHS/PSS perspective.† † Salisbury C, man M- S, Chaplin 
K, Mann C, Bower P, Brookes S, et al. A patient- centred 
intervention to improve the management of multimorbidity 
in general practice: The 3D RCT. Health Serv Deliv Res 
2019;7(5). NHS, National Health Service; PSS, personal 
socialservices; RCT, randomised controlled trials.
returned all questionnaires at all timepoints. 165 partici-
pants (20.7%) in the intervention arm and 125 (16.7%) 
in the control arm did not return a questionnaire at one 
or more follow- up points (p=0.04). Not all those who did 
return questionnaires completed the resource- use ques-
tions; in total, 181 (22.7%) in the intervention arm and 
146 (19.5%) in the control arm were missing resource- use 
data from questionnaires at one or more follow- up points 
(p=0.12). Complete data sets were available for 1191 
participants in total (599 (75.2%) in the 3D arm and 
592 (79%) in the control arm, p=0.07). Participants with 
missing data were in a significantly poorer health state at 
baseline (mean (95% CI) EQ- 5D- 5L score: 0.453 (0.422 
to 0.485)) than participants with full data sets (mean 
(95% CI) EQ- 5D- 5L score: 0.589 (0.574 to 0.605)).
Primary analysis
Outcomes and resource use
The primary analysis using imputed data showed that 
participants in the intervention arm gained a mean of 
0.007 (95% CI: −0.009 to 0.023) additional QALYs over 15 
months compared with participants in the usual care arm. 
Total costs per patient from the NHS/PSS perspective 
were £126 (95% CI: -£739 to £991) higher in the inter-
vention arm than in the usual care arm. Wide variability 
was observed in both costs and outcomes, with both CIs 
overlapping zero. Disaggregated resource- use data are in 
online supplementary appendix 3.14
Cost-effectiveness of 3D
Cost- effectiveness statistics from the NHS/PSS perspec-
tive are given in table 2.14 The ICER was £18 499, and 
the net monetary benefit at a societal willingness- to- pay 
value of £20 000 was £10 (95% CI: -£956 to £977). At 
this willingness- to- pay value, the probability that the 3D 
approach is cost- effective was 0.508, while at £30 000, 
the probability of cost- effectiveness was 0.558. A cost- 
effectiveness acceptability curve depicting the probability 
of cost- effectiveness at a range of willingness- to- pay values 
is given in figure 2.14
sensitivity analyses
Results from an analysis restricted to complete cases 
only are given in table 3.14 The complete- case analysis 
suggested that the 3D approach was associated with both 
lower costs and better outcomes, with a probability of cost- 
effectiveness of 0.705 at a willingness- to- pay threshold of 
£20 000. A sensitivity analysis excluding participants who 
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Table 3 Sensitivity analysis: cost- effectiveness of the 3D approach from an NHS/PSS perspective based on complete cases 
only
Usual care
mean (SE)
n=592 complete cases
Intervention
mean (SE)
n=599 complete cases
Incremental difference 
(95% CI)
Costs (£)
  Unadjusted costs from the NHS/PSS 
perspective
4916 (290) 4757 (222)
  Adjusted costs from the NHS/PSS 
perspective
4905 (258) 4768 (256) −137 (−852 to 577)
Outcomes
  Unadjusted QALYs over 15 months of 
follow- up
0.698 (0.014) 0.750 (0.013)
  Adjusted QALYs over 15 months of follow- 
up
0.722 (0.005) 0.726 (0.005) 0.004 (−0.010 to 0.019)
Cost- effectiveness statistics
ICER: Intervention dominates
Net monetary benefit at £20,000: £222 (−584 to 1028).
Cost estimates were adjusted for randomisation variables; QALY estimates were adjusted for randomisation variables and baseline utility.
CI, confidence interval; ICER, incremental cost- effectiveness ratio; NHS, National Health Service; PSS, personal social services; QALY, 
quality- adjusted life year; SE, standard error.
died suggested that the probability of cost- effectiveness of 
the 3D approach at £20 000 was 0.561. A further sensitivity 
analysis using undiscounted costs and outcomes did not 
suggest that the discount rate affected the conclusions.
Cost–consequences analysis
Costs and selected outcomes (on an available case basis) 
are presented in table 414 from the primary perspective 
of the NHS/PSS and the secondary perspective of the 
patient/carer themselves alongside an estimate of the 
societal loss of productivity.
Costs from all perspectives were very similar between 
arms and no cost group differed significantly (other than 
those associated with the intervention itself). Other than 
for day case/outpatient care, emergency care and medi-
cations, costs to the NHS were higher in the intervention 
arm than in the usual care arm, while social services usage 
was higher in the usual care arm. Overall costs (based 
on available data) from the NHS/PSS perspective were 
slightly higher in the usual care arm although the differ-
ence was consistent with a chance finding.
Costs borne by patients and carers were higher overall 
in the intervention arm, although the medication costs 
(both prescription charges and over- the- counter reme-
dies) were slightly lower; no patient cost group exhib-
ited a statistically significant difference. The cost of 
productivity losses was similar in the two arms (and 
statistically consistent with chance), although slightly 
higher in the 3D approach arm.
QALYs (adjusted for baseline utility scores) were 
slightly higher for patients and lower for carers in the 
intervention arm than in the usual care arm; however, 
the difference was consistent with chance. Although 
there was a higher number of deaths in the interven-
tion arm, the difference was not statistically significant.
DIsCussIOn
Principal findings
No significant difference was observed between partici-
pants offered the 3D intervention and those receiving 
usual care only for overall costs, resource use of any cate-
gory or QALY outcomes. The participants were substan-
tial users of healthcare, with inpatient hospital care and 
medications both high contributors to overall costs. A 
small improvement in outcome (representing an addi-
tional 2.6 days of the best imaginable health over 15 
months) coupled with a small increase in costs between 
arms led to weak evidence for the cost- effectiveness of 
the 3D approach in the primary analysis from the NHS/
PSS perspective. The net monetary benefit was small, but 
positive, indicating that society is willing to pay for the 
benefits that can be achieved.
strengths and limitations
This economic evaluation was conducted alongside a 
large and rigorous RCT. Meticulous data collection prac-
tices allowed individual patient data to be measured for 
all the key cost drivers, a particularly challenging task 
for a patient group that has high healthcare usage. The 
study contributes to the body of evidence supporting the 
care of patients with multimorbidity. Patterns of missing 
resource- use data were similar between arms, and high 
questionnaire return rates were achieved36; however, the 
recall period for resource- use was quite long at 9 months, 
which may have led to patients omitting to include some 
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Table 4 Costs and consequences of the 3D approach and usual care
Costs and outcomes Usual care N Intervention N Difference (95% CI)
Mean costs from the NHS perspective (£)
  Practice- based consultations 627 754 726 715 99 (−7 to 205)
  Practice- based investigations 45 755 61 717 15 (−6 to 37)
  Community- based healthcare 160 615 167 601 7 (−35 to 49)
  Inpatient stays 1867 766 1920 722 52 (−470 to 574)
  Outpatient visits and day cases 614 766 613 722 −1 (−168 to 167)
  Accident and emergency visits 102 766 99 722 −3 (−24 to 19)
  Ambulance trips to hospital 131 615 141 601 10 (−56 to 77)
  Prescribed medications 1230 755 1221 717 −8 (−220 to 203)
  Pharmacy reviews 0 766 8 722 8 (7 to 9)
  Intervention set up 0 797 4 749 4 (3 to 5)
  Social services 559 615 403 601 −156 (−476 to 164)
  All NHS/PSS 4929 609 4746 598 −183 (−923 to 556)
Mean costs from the patient/carer perspective (£)
  Prescription charges 5 755 4 717 −2 (−6 to 2)
  Travel to GP practice 24 749 34 711 10 (−4 to 24)
  Over- the- counter medications 39 615 35 601 −3 (−16 to 9)
  Private healthcare 93 615 122 601 29 (−40 to 97)
  All patient/carer 162 608 195 597 33 (−35 to 101)
Mean productivity loss (£)
  Productivity loss 122 608 161 597 39 (−47 to 125)
  Outcomes
  QALYs (patient) 0.693 665 0.695 647 0.003 (−0.013 to 0.019)
  QALYs (carer) 0.943 41 0.920 50 −0.024 (−0.064 to 0.017)
  Deaths 32 749 46 797 p=0.18 (χ2 test)
All costs and consequences are based on available data; the totals from each perspective are not, therefore, equal to the sum of the 
components. CI were calculated using SEs from standard linear regressions adjusted for cluster at the level of the practice. QALYs were 
adjusted for baseline utility scores.
CI, confidence interval; GP, general practitioner; NHS, National Health Service; PSS, personal social services; QALY, quality- adjusted life year.
resources. Medication costs were based on prescriptions 
issued by the GP, and it is not certain that all scripts 
were filled by the participant; the medication costs may, 
therefore, be overestimated. Although the medication 
data were checked carefully, the volume of medications 
prescribed to the 3D population rendered it infeasible to 
check every entry and some errors may have persisted.
Use of care homes, which can be a significant contrib-
utor to costs of social care, was not included in the 
economic evaluation. The funding of care homes within 
the UK is complex, with patients often paying consider-
able amounts themselves. However, only 13 participants 
reported living in a care home and this did not differ by 
arm. The follow- up period of the 3D trial was 15 months, 
and longer- term outcomes are unknown; a follow- up 
period of 2 to 3 years might have allowed an effect on 
quality of life or healthcare resource use to be observed. 
Use of simple mean imputation methods for estimating 
missing information (such as the cost of a bus fare) in the 
questionnaire data will have reduced SEs and underesti-
mated the uncertainty around these costs.
Comparison with other studies
Comparison with other studies is hampered by the variety 
of definitions used for multimorbidity, and by the hetero-
geneity in study designs.11 Evidence concerning the cost- 
effectiveness of interventions designed to manage patients 
with multimorbidity is limited; only two of the RCTs identi-
fied in the review by Smith et al undertook cost- effectiveness 
analyses.7 Katon et al reported that implementation of a 
collaborative care intervention for patients with depression 
alongside either diabetes or coronary heart disease was justi-
fied on cost- effectiveness grounds.37 However, the authors 
estimated QALYs based on clinical outcomes rather than by 
direct measurement, and there was substantial uncertainty 
around both costs and outcomes. Barley et al found that a 
nurse- led patient- centred intervention was cost- effective up 
to a willingness- to- pay threshold of approximately £3000 
per QALY; however, the study was only a pilot RCT, and 
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multimorbidity was defined to include patients with coro-
nary heart disease and depression only.38 In a feasibility 
trial, Mercer et al found that a whole- system intervention 
designed for patients with two or more chronic condi-
tions in deprived areas may be considered cost- effective.39 
There is a clear need for further well conducted studies 
on the cost- effectiveness of interventions for multimorbid 
patients.
Implications of study
This is the largest trial of an intervention for multimor-
bidity ever undertaken; however, there remains substan-
tial uncertainty surrounding the results. The impact of 
organisational changes in delivery of primary healthcare 
on patients’ quality of life is usually very small and the 
costs are also usually low, but skewed by a small number 
of patients with high costs in secondary care often unre-
lated to the intervention. This leads to wide CIs that cross 
zero (ie, substantial uncertainty) for estimates of cost- 
effectiveness and illustrates the difficulty of obtaining 
precise estimates for the economic outcomes of this type 
of intervention even in large trials.
The 3D participants had a mean(SD) utility of 0.558 
(0.287) at entry to the study, which compares poorly to a 
UK population mean of 0.779 for ages 65 to 7440. Partici-
pants had a small positive increase in QALYs in the inter-
vention arm, while carers had a small decrease in QALYs 
compared with the usual care arm; it is possible that an 
analysis taking carer outcomes into account might reach 
a different conclusion. The small contribution to overall 
costs made by productivity losses is consistent with the 
predominantly retired study population; at baseline, over 
65% of participants described themselves as ‘fully retired 
from work’.
Anticipated reductions in appointment attendances 
were not achieved, partly because some patients 
attended 3D reviews in addition to, rather than instead 
of, their single- condition reviews. Similarly, although 
cost savings could have been achieved through a reduc-
tion in prescriptions issued, this was not observed in the 
trial; although the brief was to seek to simplify patients’ 
medication regimes, the embedded process evaluation14 
suggested that pharmacists appeared to concentrate on 
adherence to guidelines rather than whether the patient 
might benefit from stopping some medications. There 
was substantial variation between practices in the extent 
to which they implemented the intervention and this may 
have contributed to variation in costs in the trial arm. 
Three practices barely implemented the intervention at 
all because of practice or staffing problems unconnected 
with the intervention, and this will have diluted the 
potential effects of the intervention overall. It is possible 
that the cost- effectiveness of the intervention could be 
increased by focusing more on patients with the greatest 
needs, by more attention to de- prescribing and by ending 
unnecessary additional disease- specific reviews as the 3D 
model became normalised.
Future work
The EQ- 5D instrument was used because it is recom-
mended by NICE in the UK,26 and there was little 
evidence on alternatives at the trial outset. However, it is 
difficult to pick up small changes in health- related quality 
of life arising from service reconfigurations, and it may 
be that a measure capturing outcomes beyond health 
would be more appropriate. In future work, researchers 
should consider including alternative economic outcome 
measures alongside the EQ- 5D; for example, the ICECAP 
suite of capability well- being instruments.41 The effect of 
the intervention on carers is being considered further, 
and it would be interesting to explore the reasons for the 
errors observed in the medication records downloaded 
from GP practice systems.
COnClusIOns
The evidence for the cost- effectiveness of the 3D interven-
tion is equivocal; the results suggest that there is just over a 
50% chance of cost- effectiveness at the established threshold 
of £20 000 per QALY from the NHS/PSS perspective. The 
small differences in costs and outcomes are consistent with 
chance, and the uncertainty is substantial; therefore, the 
results should be interpreted with caution. Given the equiv-
ocal nature of the cost- effectiveness results, implementation 
of the intervention cannot be recommended on economic 
grounds alone.
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